Annual EBITDA
$4.42 B
-$11.60 M-0.26%
31 December 2023
Summary:
Vertex Pharmaceuticals Incorporated annual earnings before interest, taxes, depreciation & amortization is currently $4.42 billion, with the most recent change of -$11.60 million (-0.26%) on 31 December 2023. During the last 3 years, it has risen by +$1.14 billion (+34.69%). VRTX annual EBITDA is now -0.26% below its all-time high of $4.44 billion, reached on 31 December 2022.VRTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$1.23 B
+$4.56 B+137.01%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated quarterly earnings before interest, taxes, depreciation & amortization is currently $1.23 billion, with the most recent change of +$4.56 billion (+137.01%) on 30 September 2024. Over the past year, it has dropped by -$600.00 thousand (-0.05%). VRTX quarterly EBITDA is now -8.29% below its all-time high of $1.34 billion, reached on 31 March 2024.VRTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$464.50 M
-$600.00 K-0.13%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated TTM earnings before interest, taxes, depreciation & amortization is currently $464.50 million, with the most recent change of -$600.00 thousand (-0.13%) on 30 September 2024. Over the past year, it has dropped by -$4.05 billion (-89.71%). VRTX TTM EBITDA is now -90.72% below its all-time high of $5.01 billion, reached on 31 March 2024.VRTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRTX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -0.3% | -0.1% | -89.7% |
| 3 y3 years | +34.7% | +9.0% | -84.2% |
| 5 y5 years | +493.7% | +1008.9% | -49.1% |
VRTX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -0.3% | +51.6% | -8.3% | +137.0% | -90.7% | at low |
| 5 y | 5 years | -0.3% | +493.7% | -8.3% | +137.0% | -90.7% | at low |
| alltime | all time | -0.3% | +727.6% | -8.3% | +137.0% | -90.7% | +165.8% |
Vertex Pharmaceuticals Incorporated EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.23 B(-137.0%) | $464.50 M(-0.1%) |
| June 2024 | - | -$3.33 B(-347.8%) | $465.10 M(-90.7%) |
| Mar 2024 | - | $1.34 B(+10.3%) | $5.01 B(+8.7%) |
| Dec 2023 | $4.42 B(-0.3%) | $1.22 B(-1.2%) | $4.61 B(+2.0%) |
| Sept 2023 | - | $1.23 B(+1.5%) | $4.51 B(+0.1%) |
| June 2023 | - | $1.21 B(+28.9%) | $4.51 B(+3.2%) |
| Mar 2023 | - | $941.70 M(-16.4%) | $4.37 B(-1.4%) |
| Dec 2022 | $4.44 B(+52.0%) | $1.13 B(-8.2%) | $4.44 B(+4.9%) |
| Sept 2022 | - | $1.23 B(+14.0%) | $4.23 B(+2.4%) |
| June 2022 | - | $1.08 B(+7.0%) | $4.13 B(+35.1%) |
| Mar 2022 | - | $1.01 B(+9.3%) | $3.06 B(+4.8%) |
| Dec 2021 | $2.92 B(-11.2%) | $919.80 M(-18.6%) | $2.92 B(-0.5%) |
| Sept 2021 | - | $1.13 B(>+9900.0%) | $2.93 B(+13.3%) |
| June 2021 | - | $2.60 M(-99.7%) | $2.59 B(-25.0%) |
| Mar 2021 | - | $865.40 M(-7.4%) | $3.45 B(+5.1%) |
| Dec 2020 | $3.28 B(+110.5%) | $934.40 M(+18.8%) | $3.28 B(+7.1%) |
| Sept 2020 | - | $786.37 M(-9.1%) | $3.07 B(+28.2%) |
| June 2020 | - | $865.34 M(+23.9%) | $2.39 B(+26.1%) |
| Mar 2020 | - | $698.49 M(-2.6%) | $1.90 B(+21.6%) |
| Dec 2019 | $1.56 B(+109.4%) | $717.39 M(+545.9%) | $1.56 B(+70.9%) |
| Sept 2019 | - | $111.06 M(-70.0%) | $912.97 M(-6.5%) |
| June 2019 | - | $369.67 M(+2.1%) | $976.30 M(+13.6%) |
| Mar 2019 | - | $362.17 M(+416.9%) | $859.43 M(+15.3%) |
| Dec 2018 | $745.13 M(+547.9%) | $70.07 M(-59.8%) | $745.13 M(-10.0%) |
| Sept 2018 | - | $174.39 M(-31.0%) | $828.23 M(+212.0%) |
| June 2018 | - | $252.81 M(+2.0%) | $265.47 M(+241.5%) |
| Mar 2018 | - | $247.87 M(+61.8%) | $77.73 M(-32.4%) |
| Dec 2017 | $115.01 M(+52.4%) | $153.17 M(-139.4%) | $115.01 M(+537.8%) |
| Sept 2017 | - | -$388.37 M(-696.9%) | $18.03 M(-95.5%) |
| June 2017 | - | $65.06 M(-77.2%) | $402.08 M(+13.5%) |
| Mar 2017 | - | $285.15 M(+407.4%) | $354.12 M(+369.3%) |
| Dec 2016 | $75.46 M(-118.3%) | $56.20 M(-1399.3%) | $75.46 M(-470.3%) |
| Sept 2016 | - | -$4.33 M(-125.3%) | -$20.38 M(-71.4%) |
| June 2016 | - | $17.10 M(+163.2%) | -$71.24 M(-70.8%) |
| Mar 2016 | - | $6.50 M(-116.4%) | -$244.02 M(-40.7%) |
| Dec 2015 | -$411.25 M(-31.3%) | -$39.65 M(-28.2%) | -$411.25 M(-19.8%) |
| Sept 2015 | - | -$55.18 M(-64.6%) | -$512.68 M(-12.6%) |
| June 2015 | - | -$155.69 M(-3.1%) | -$586.73 M(+4.8%) |
| Mar 2015 | - | -$160.74 M(+13.9%) | -$559.69 M(-6.5%) |
| Dec 2014 | -$598.75 M(+7.9%) | -$141.08 M(+9.2%) | -$598.75 M(+34.0%) |
| Sept 2014 | - | -$129.23 M(+0.5%) | -$446.79 M(+4.7%) |
| June 2014 | - | -$128.64 M(-35.6%) | -$426.88 M(+23.9%) |
| Mar 2014 | - | -$199.80 M(-1936.4%) | -$344.64 M(-39.9%) |
| Dec 2013 | -$554.75 M(-750.9%) | $10.88 M(-110.0%) | -$573.63 M(-5.4%) |
| Sept 2013 | - | -$109.32 M(+135.6%) | -$606.55 M(+24.0%) |
| June 2013 | - | -$46.41 M(-89.2%) | -$489.02 M(+10.1%) |
| Mar 2013 | - | -$428.78 M(+1844.7%) | -$444.13 M(-621.1%) |
| Dec 2012 | $85.23 M(-36.0%) | -$22.05 M(-368.3%) | $85.23 M(-74.9%) |
| Sept 2012 | - | $8.22 M(-643.9%) | $339.46 M(-37.9%) |
| June 2012 | - | -$1.51 M(-101.5%) | $546.66 M(+40.5%) |
| Mar 2012 | - | $100.57 M(-56.7%) | $388.97 M(+192.1%) |
| Dec 2011 | $133.17 M(-118.9%) | $232.18 M(+7.8%) | $133.17 M(-150.5%) |
| Sept 2011 | - | $215.42 M(-235.3%) | -$263.52 M(-61.1%) |
| June 2011 | - | -$159.20 M(+2.6%) | -$677.18 M(-4.1%) |
| Mar 2011 | - | -$155.24 M(-5.6%) | -$706.40 M(+0.5%) |
| Dec 2010 | -$704.89 M(+17.7%) | -$164.50 M(-17.0%) | -$703.08 M(-0.1%) |
| Sept 2010 | - | -$198.25 M(+5.2%) | -$703.96 M(+8.9%) |
| June 2010 | - | -$188.41 M(+24.0%) | -$646.36 M(+6.6%) |
| Mar 2010 | - | -$151.92 M(-8.1%) | -$606.26 M(+1.2%) |
| Dec 2009 | -$598.88 M(+40.5%) | -$165.39 M(+17.6%) | -$598.88 M(+6.0%) |
| Sept 2009 | - | -$140.64 M(-5.2%) | -$565.14 M(+3.5%) |
| June 2009 | - | -$148.31 M(+2.6%) | -$546.29 M(+13.8%) |
| Mar 2009 | - | -$144.53 M(+9.8%) | -$480.11 M(+12.7%) |
| Dec 2008 | -$426.19 M(+10.6%) | -$131.65 M(+8.1%) | -$426.19 M(+12.6%) |
| Sept 2008 | - | -$121.79 M(+48.3%) | -$378.56 M(+4.3%) |
| June 2008 | - | -$82.14 M(-9.3%) | -$362.85 M(-9.0%) |
| Mar 2008 | - | -$90.61 M(+7.8%) | -$398.57 M(+3.5%) |
| Dec 2007 | -$385.21 M | -$84.02 M(-20.8%) | -$385.21 M(+17.4%) |
| Sept 2007 | - | -$106.08 M(-10.0%) | -$328.23 M(+18.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2007 | - | -$117.86 M(+52.6%) | -$276.93 M(+19.9%) |
| Mar 2007 | - | -$77.25 M(+185.8%) | -$231.03 M(+15.8%) |
| Dec 2006 | -$199.52 M(+74.3%) | -$27.03 M(-50.7%) | -$199.52 M(+7.5%) |
| Sept 2006 | - | -$54.78 M(-23.9%) | -$185.59 M(+12.7%) |
| June 2006 | - | -$71.97 M(+57.3%) | -$164.70 M(+30.2%) |
| Mar 2006 | - | -$45.74 M(+249.0%) | -$126.54 M(+10.6%) |
| Dec 2005 | -$114.45 M(+6.4%) | -$13.11 M(-61.3%) | -$114.45 M(-5.7%) |
| Sept 2005 | - | -$33.89 M(+0.2%) | -$121.40 M(+6.2%) |
| June 2005 | - | -$33.81 M(+0.5%) | -$114.33 M(+0.6%) |
| Mar 2005 | - | -$33.65 M(+67.8%) | -$113.63 M(+5.6%) |
| Dec 2004 | -$107.59 M(-27.9%) | -$20.05 M(-25.2%) | -$107.59 M(-10.2%) |
| Sept 2004 | - | -$26.82 M(-19.0%) | -$119.82 M(-10.9%) |
| June 2004 | - | -$33.11 M(+20.0%) | -$134.43 M(-26.5%) |
| Mar 2004 | - | -$27.61 M(-14.5%) | -$182.87 M(+42.0%) |
| Dec 2003 | -$149.26 M(+21.3%) | -$32.28 M(-22.1%) | -$128.81 M(-15.1%) |
| Sept 2003 | - | -$41.43 M(-49.2%) | -$151.77 M(+8.7%) |
| June 2003 | - | -$81.55 M(-408.2%) | -$139.62 M(+84.1%) |
| Mar 2003 | - | $26.45 M(-147.9%) | -$75.82 M(-38.4%) |
| Dec 2002 | -$123.05 M(+26.7%) | -$55.25 M(+88.7%) | -$123.05 M(+0.7%) |
| Sept 2002 | - | -$29.28 M(+65.0%) | -$122.20 M(+14.6%) |
| June 2002 | - | -$17.75 M(-14.6%) | -$106.66 M(+3.2%) |
| Mar 2002 | - | -$20.78 M(-61.8%) | -$103.31 M(+8.3%) |
| Dec 2001 | -$97.14 M(+294.0%) | -$54.39 M(+295.7%) | -$95.40 M(+99.7%) |
| Sept 2001 | - | -$13.74 M(-4.5%) | -$47.77 M(+1.9%) |
| June 2001 | - | -$14.39 M(+11.8%) | -$46.89 M(+123.9%) |
| Mar 2001 | - | -$12.87 M(+90.2%) | -$20.94 M(-12.8%) |
| Dec 2000 | -$24.65 M(-44.4%) | -$6.77 M(-47.4%) | -$24.01 M(+51.5%) |
| Sept 2000 | - | -$12.86 M(-211.2%) | -$15.85 M(-9.9%) |
| June 2000 | - | $11.56 M(-172.5%) | -$17.59 M(-56.9%) |
| Mar 2000 | - | -$15.95 M(-1242.3%) | -$40.85 M(-7.4%) |
| Dec 1999 | -$44.30 M(+2.5%) | $1.40 M(-109.6%) | -$44.11 M(-38.5%) |
| Sept 1999 | - | -$14.60 M(+24.8%) | -$71.70 M(+23.4%) |
| June 1999 | - | -$11.70 M(-39.0%) | -$58.10 M(+5.8%) |
| Mar 1999 | - | -$19.20 M(-26.7%) | -$54.90 M(+16.6%) |
| Dec 1998 | -$43.20 M(+176.9%) | -$26.20 M(+2520.0%) | -$47.10 M(+78.4%) |
| Sept 1998 | - | -$1.00 M(-88.2%) | -$26.40 M(-12.3%) |
| June 1998 | - | -$8.50 M(-25.4%) | -$30.10 M(+36.8%) |
| Mar 1998 | - | -$11.40 M(+107.3%) | -$22.00 M(+42.9%) |
| Dec 1997 | -$15.60 M(-57.0%) | -$5.50 M(+17.0%) | -$15.40 M(-36.9%) |
| Sept 1997 | - | -$4.70 M(+1075.0%) | -$24.40 M(-7.2%) |
| June 1997 | - | -$400.00 K(-91.7%) | -$26.30 M(-21.0%) |
| Mar 1997 | - | -$4.80 M(-66.9%) | -$33.30 M(-8.3%) |
| Dec 1996 | -$36.30 M(+59.2%) | -$14.50 M(+119.7%) | -$36.30 M(+57.1%) |
| Sept 1996 | - | -$6.60 M(-10.8%) | -$23.10 M(-1.7%) |
| June 1996 | - | -$7.40 M(-5.1%) | -$23.50 M(-8.6%) |
| Mar 1996 | - | -$7.80 M(+500.0%) | -$25.70 M(+12.7%) |
| Dec 1995 | -$22.80 M(+32.6%) | -$1.30 M(-81.4%) | -$22.80 M(-21.1%) |
| Sept 1995 | - | -$7.00 M(-27.1%) | -$28.90 M(+16.1%) |
| June 1995 | - | -$9.60 M(+95.9%) | -$24.90 M(+25.8%) |
| Mar 1995 | - | -$4.90 M(-33.8%) | -$19.80 M(+15.1%) |
| Dec 1994 | -$17.20 M(-437.3%) | -$7.40 M(+146.7%) | -$17.20 M(>+9900.0%) |
| Sept 1994 | - | -$3.00 M(-33.3%) | -$100.00 K(-111.1%) |
| June 1994 | - | -$4.50 M(+95.7%) | $900.00 K(-83.6%) |
| Mar 1994 | - | -$2.30 M(-123.7%) | $5.50 M(+7.8%) |
| Dec 1993 | $5.10 M(-170.8%) | $9.70 M(-585.0%) | $5.10 M(-175.0%) |
| Sept 1993 | - | -$2.00 M(-2100.0%) | -$6.80 M(+1.5%) |
| June 1993 | - | $100.00 K(-103.7%) | -$6.70 M(-19.3%) |
| Mar 1993 | - | -$2.70 M(+22.7%) | -$8.30 M(+16.9%) |
| Dec 1992 | -$7.20 M(+89.5%) | -$2.20 M(+15.8%) | -$7.10 M(+16.4%) |
| Sept 1992 | - | -$1.90 M(+26.7%) | -$6.10 M(+17.3%) |
| June 1992 | - | -$1.50 M(0.0%) | -$5.20 M(+15.6%) |
| Mar 1992 | - | -$1.50 M(+25.0%) | -$4.50 M(+104.5%) |
| Dec 1991 | -$3.80 M(-7.3%) | -$1.20 M(+20.0%) | -$2.20 M(-67.6%) |
| Sept 1991 | - | -$1.00 M(+25.0%) | -$6.80 M(+30.8%) |
| June 1991 | - | -$800.00 K(-200.0%) | -$5.20 M(+36.8%) |
| Mar 1991 | - | $800.00 K(-113.8%) | -$3.80 M(-7.3%) |
| Dec 1990 | -$4.10 M | -$5.80 M(-1066.7%) | -$4.10 M(-341.2%) |
| Sept 1990 | - | $600.00 K(0.0%) | $1.70 M(+54.5%) |
| June 1990 | - | $600.00 K(+20.0%) | $1.10 M(+120.0%) |
| Mar 1990 | - | $500.00 K | $500.00 K |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual EBITDA year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly EBITDA year-on-year change?
- What is Vertex Pharmaceuticals Incorporated TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated TTM EBITDA year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of VRTX is $4.42 B
What is the all time high annual EBITDA for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual earnings before interest, taxes, depreciation & amortization is $4.44 B
What is Vertex Pharmaceuticals Incorporated annual EBITDA year-on-year change?
Over the past year, VRTX annual earnings before interest, taxes, depreciation & amortization has changed by -$11.60 M (-0.26%)
What is Vertex Pharmaceuticals Incorporated quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of VRTX is $1.23 B
What is the all time high quarterly EBITDA for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly earnings before interest, taxes, depreciation & amortization is $1.34 B
What is Vertex Pharmaceuticals Incorporated quarterly EBITDA year-on-year change?
Over the past year, VRTX quarterly earnings before interest, taxes, depreciation & amortization has changed by -$600.00 K (-0.05%)
What is Vertex Pharmaceuticals Incorporated TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of VRTX is $464.50 M
What is the all time high TTM EBITDA for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high TTM earnings before interest, taxes, depreciation & amortization is $5.01 B
What is Vertex Pharmaceuticals Incorporated TTM EBITDA year-on-year change?
Over the past year, VRTX TTM earnings before interest, taxes, depreciation & amortization has changed by -$4.05 B (-89.71%)